ASXL1 as a critical regulator of epigenetic marks and therapeutic potential of mutated cells
Oncotarget
.
2018 Oct 16;9(81):35203-35204.
doi: 10.18632/oncotarget.26230.
Authors
Daichi Inoue
1
,
Takeshi Fujino
1
,
Toshio Kitamura
1
Affiliation
1
Daichi Inoue: Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, Zuckerman, New York, NY, USA.
PMID:
30443287
PMCID:
PMC6219660
DOI:
10.18632/oncotarget.26230
No abstract available
Keywords:
ASXL1; H2AK119Ub; H3K4me3; MDS; OGT.
Publication types
Editorial
Grants and funding
P30 CA008748/CA/NCI NIH HHS/United States